Fortrea (FTRE) Jefferies Global Healthcare Conference 2026 summary

Market and demand trends

• Demand environment has improved steadily, with constructive dialogues and increased RFP flow from both large pharma and biotech segments.

• Biotech demand, especially in the U.S., has rebounded, and clinical pharmacology is seeing faster recovery and ramp-up.

• Bookings strength is reflected in a robust sales pipeline, with recent biotech funding expected to translate into bookings over the next quarters.

• Business development and licensing (BD&L) activity, including M&A and asset licensing, is contributing additional demand beyond traditional financing.

Revenue, margin, and cost management

• Revenue is expected to decline by about 4.5% for the year, mainly due to reduced pass-throughs and prior soft bookings, but underlying service fee revenue is trending toward flat by year-end.

• Cost savings targets for the year are $70–80 million gross and $40–50 million net, achieved through careful cost identification, facilities rationalization, and leveraging third parties.

• Employee engagement and customer NPS scores have improved, indicating successful balance between cost management and service quality.

• Cost-cutting is positioned as a cultural shift toward efficiency and effectiveness, with employees encouraged to identify improvements.

Sales strategy and client management

• Sales approach has shifted to a holistic model involving commercial, operational, finance, and legal teams, with tailored strategies for large pharma and biotech clients.

• Incentives for leaders are tied to revenue, EBITDA, and net bookings, aligning all functions toward growth and delivery.

• Selectivity in FSP contracts is emphasized, with strategic decisions to retain key clients even with price concessions, aiming for long-term service line growth.

• Client concentration is decreasing as growth diversifies the portfolio, with large clients providing scale and capability-building opportunities.